Researchers analyse SARS-CoV-2 genome, identifying 198 mutations
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
List view / Grid view
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
A molecule called microRNA-744, which influences inflammation, has been revealed by researchers as a new drug target for Sjögren's Syndrome.
Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
High-resolution mass spectrometry has been used by researchers to map the glycan-processing states of the Spike protein of the SARS-CoV-2 virus, which causes COVID-19.
According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
Researchers have uncovered the structure of nonribosomal peptide synthetases (NRPSs), an important ingredient in drug production.
According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.